All Over But The Lawsuits? NCE Exclusivity For Fixed-Dose Combos Remains Prospective
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA rejects requests by firms to make new policy retroactive; Gilead’s Harvoni and Eisai’s Akynzeo fixed combos, approved the day FDA issued its final guidance, granted exclusivity.
You may also be interested in...
Fixed Combinations Of ‘Old Antibiotic’ Plus New Moiety Eligible For NCE Exclusivity, US FDA Says
A 2008 law that limited exclusivity for certain antibiotics to three years does not apply to Allergan’s Avycaz, which combines an approved old antibiotic active moiety and a new active moiety, CDER exclusivity board concludes.
Pfizer Presses FDA To Revise Combo Drug Exclusivity Policy For Duavee
Citizen petition seeks five-year NCE exclusivity for Pfizer’s estrogen/bazedoxifene combo after district court tells FDA its inconsistent position is unreasonable.
Ferring Wins In Combo Exclusivity Case; FDA Lacks 'Legitimate Reason' To Reject
Court finds FDA erred in not giving the fixed-dose combo product Prepopik five years of market exclusivity since it had awarded the exclusivity to similarly situated single-entity drug products.